Industry Experts

Sebastian Steiniger, PhD, is VP of Translational Sciences at RyboDyn, Inc., where he leads the discovery of pMHC-targeted TCR-mimic antibodies, ADCs, and T-cell engagers against the dark proteome. With Over 15+ years of experience in developing biologics, he has built protein-engineering platforms at Arrowhead Pharma, Rakuten Medical, Zoetis/Pfizer, advancing multiple candidates into IND-enabling studies. He was lead engineer for bedinvetmab (Librela™), an FDA-approved anti-NGF antibody with millions of doses sold, and holds eight issued patents. He trained at ETH Zürich, Switzerland and the University of Greifswald, Germany, earned his PhD at Goethe University Frankfurt, Germany and conducted post-doctoral studies in the Janda laboratory at the Scripps Research Institute in La Jolla, California.